Browsing Tag
NYSE: AORT
1 post
Artivion (NYSE: AORT) begins pivotal Arcevo LSA trial: Could this hybrid stent unlock an $80m U.S. market?
Artivion begins pivotal ARTIZEN trial with first patient treated using Arcevo LSA. Find out how this hybrid stent could transform aortic arch surgery.